23 July 2015.
The Generic Medicines Industry Association (GMiA) is announcing that Mr. Mark Crotty is stepping down from the position of Chair effective July 24 2015.
Mr. Crotty became Chair in July 2013 for a two year period with the goal of strengthening the GMiA. In this time he has been an agent of change, driving a strategic approach that focused on ensuring the long-term viability of the generic and biosimilar sector. In a time of significant change and uncertainty for the pharmaceutical industry, he reorganised the GMiA, reshaping its relationship with government and strengthening its role in industry policy.
“2013-2015 saw many tough changes in Australian pharma. Through this time, The Board ensured that the GMiA remained relevant and the executive team worked successfully to engage our members and government. We have built a stronger, more focused organisation in two short years and our members can look forward with confidence and optimism. I thank the Board, Executive and members for their unified approach and support during this time,” said Mr Crotty.
In 2014, the Commission of Audit became a platform to establish a clear mandate for generic and biosimilar medicines in Australia and the unintended consequences of PBS pricing policies. This led to a disciplined campaign to build high levels of trust among members and government, positioning the GMiA for both the 2015 budget negotiations and the resulting PBS reforms.
The Strategic Agreement negotiated with Minister Ley and the Department of Health was the first to recognise the essential role of generic medicines and biosimilars in delivering affordable healthcare through the Pharmaceutical Benefits Scheme (PBS). It will support the ongoing supply of affordable generic and biosimilar medicines in Australia and deliver a 5 year period of certainty for GMiA members.
The GMiA Board thanks Mark for his strong leadership and dedication to the generic and biosimilar medicines industry.
The announcement of the new GMiA Chair will be made on 3 August 2015.
